Hims & Hers Health (NYSE:HIMS) Reaches New 52-Week Low – Here’s Why

Hims & Hers Health, Inc. (NYSE:HIMS) hit a new 52-week low during trading on Friday . The stock traded as low as $22.95 and last traded at $23.4970, with a volume of 69296098 shares trading hands. The stock had previously closed at $24.40.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS is expanding its care stack by adding multicancer screening (Grail’s Galleri) to its platform, which can increase revenue per patient and strengthen its diagnostics-to-care ecosystem. Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
• Positive Sentiment: Analysts note HIMS is scaling a platform-led digital healthcare model (Labs, AI, YourBio Health) that could lift margins and stickiness if execution continues. Hims & Hers Strengthens Platform-Led Digital Healthcare Model
• Neutral Sentiment: Market response has been volatile: initial share gains after the $49 semaglutide reveal were followed by declines as legal and regulatory reactions emerged; expect elevated volume and short-term price swings. Hims’ $49 weight-loss pill rattles investor case for cash-pay obesity market
• Negative Sentiment: Novo Nordisk has publicly accused HIMS of illegal mass compounding and has vowed legal action, creating litigation risk, potential injunctions, and reputation/partnership fallout. Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version
• Negative Sentiment: The FDA’s leadership signaled potential enforcement against mass-marketed copycat drugs, raising regulatory risk that could limit HIMS’s ability to sell compounded GLP‑1s at scale. FDA’s Makary pledges crackdown on mass marketing of ‘illegal copycat drugs’
• Negative Sentiment: Broader market impact: major pharma peers (Novo, Eli Lilly) saw share moves tied to the story, and investors are weighing potential costly legal fights, regulatory scrutiny, and patient-safety scrutiny that could blunt near-term revenue from the pill initiative. Hims & Hers falls after Novo’s legal threat

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. Leerink Partners upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Barclays assumed coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target on the stock. Finally, KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health Trading Down 2.0%

The business’s fifty day moving average price is $32.96 and its 200 day moving average price is $43.42. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $5.24 billion, a PE ratio of 42.63, a P/E/G ratio of 3.79 and a beta of 2.43.

Hims & Hers Health announced that its board has approved a stock buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This represents a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 23,187 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer owned 70,232 shares in the company, valued at approximately $2,585,239.92. The trade was a 24.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 131,974 shares of company stock worth $4,763,800. Company insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. Capital World Investors lifted its stake in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after purchasing an additional 223,892 shares in the last quarter. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the period. State Street Corp raised its holdings in Hims & Hers Health by 1.9% in the third quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after buying an additional 132,384 shares during the period. Finally, Geode Capital Management LLC lifted its position in Hims & Hers Health by 1.5% during the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after buying an additional 71,593 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.